Publications by authors named "Jay Edelberg"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

54,356

Total Likes

2,229

Extended Reach

492,783

Social Features

80
D
Danicamtiv, a Selective Agonist of Cardiac Myosin, for Dilated Cardiomyopathy: A Phase 2 Open-Label Trial.
Neal K Lakdawala, Ray E Hershberger, Pablo Garcia-Pavia, Perry Mark Elliott, Jonathan Ginns, Jay M Edelberg

J Am Coll Cardiol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient-Level Artificial Intelligence-Enhanced Electrocardiography in Hypertrophic Cardiomyopathy: Longitudinal Treatment and Clinical Biomarker Correlations.
Konstantinos C Siontis, Sean Abreau, Zachi I Attia, Joshua P Barrios, Thomas A Dewland, Jay M Edelberg

JACC Adv· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of Mavacamten on Measures of Cardiopulmonary Exercise Testing Beyond Peak Oxygen Consumption: A Secondary Analysis of the EXPLORER-HCM Randomized Trial.
Matthew T Wheeler, Iacopo Olivotto, Perry M Elliott, Sara Saberi, Anjali T Owens, Jay M Edelberg

JAMA Cardiol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of beta-blocker therapy on the response to mavacamten in patients with symptomatic obstructive hypertrophic cardiomyopathy.
Matthew T Wheeler, Daniel Jacoby, Perry M Elliott, Sara Saberi, Sheila M Hegde, Jay M Edelberg

Eur J Heart Fail· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Impact of Mavacamten on the Pathophysiology of Hypertrophic Cardiomyopathy: A Narrative Review.
Jay M Edelberg, Amy J Sehnert, Matthew E Mealiffe, Carlos L Del Rio, Robert McDowell

Am J Cardiovasc Drugs· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy.
Milind Y Desai, Anjali Owens, Jeffrey B Geske, Kathy Wolski, Srihari S Naidu, Jay M Edelberg

J Am Coll Cardiol· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of Disease Status and Treatment Response With Artificial Intelligence-Enhanced Electrocardiography in Obstructive Hypertrophic Cardiomyopathy.
Geoffrey H Tison, Konstantinos C Siontis, Sean Abreau, Zachi Attia, Priyanka Agarwal, Jay M Edelberg

J Am Coll Cardiol· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Study design and rationale of VALOR-HCM: evaluation of mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy who are eligible for septal reduction therapy.
Milind Y Desai, Kathy Wolski, Anjali Owens, Srihari S Naidu, Jeffrey B Geske, Jay M Edelberg

Am Heart J· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical and economic burden of obstructive hypertrophic cardiomyopathy in the United States.
Sneha S Jain, Sophia S Li, Jipan Xie, Megan B Sutton, Jennifer T Fine, Jay M Edelberg

J Med Econ· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of danicamtiv, a novel cardiac myosin activator, in heart failure with reduced ejection fraction: experimental data and clinical results from a phase 2a trial.
Adriaan A Voors, Jean-François Tamby, John G Cleland, Michael Koren, Leslie B Forgosh, Jay M Edelberg

Eur J Heart Fail· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial.
Iacopo Olivotto, Artur Oreziak, Roberto Barriales-Villa, Theodore P Abraham, Ahmad Masri, Jay M Edelberg

Lancet· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Time-Dependent Cardiovascular Treatment Benefit Model for Lipid-Lowering Therapies.
Irfan Khan, Eric D Peterson, Christopher P Cannon, Lauren E Sedita, Jay M Edelberg

J Am Heart Assoc· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of Mavacamten in Symptomatic Patients With Nonobstructive Hypertrophic Cardiomyopathy.
Carolyn Y Ho, Matthew E Mealiffe, Richard G Bach, Mondira Bhattacharya, Lubna Choudhury, Jay M Edelberg

J Am Coll Cardiol· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome.
Vera A Bittner, Michael Szarek, Philip E Aylward, Deepak L Bhatt, Rafael Diaz, Jay M Edelberg

J Am Coll Cardiol· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome: ODYSSEY OUTCOMES Trial.
J Wouter Jukema, Michael Szarek, Laurien E Zijlstra, H Asita de Silva, Deepak L Bhatt, Jay M Edelberg

J Am Coll Cardiol· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial.
Harvey D White, Ph Gabriel Steg, Michael Szarek, Deepak L Bhatt, Vera A Bittner, Jay M Edelberg

Eur Heart J· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery.
Shaun G Goodman, Philip E Aylward, Michael Szarek, Vakhtang Chumburidze, Deepak L Bhatt, Jay M Edelberg

J Am Coll Cardiol· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Alirocumab on Mortality After Acute Coronary Syndromes.
Philippe Gabriel Steg, Michael Szarek, Deepak L Bhatt, Vera A Bittner, Marie-France Brégeault, Jay M Edelberg

Circulation· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events: The ODYSSEY OUTCOMES Trial.
Michael Szarek, Harvey D White, Gregory G Schwartz, Marco Alings, Deepak L Bhatt, Jay M Edelberg

J Am Coll Cardiol· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term treatment adherence to the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab in 6 ODYSSEY Phase III clinical studies with treatment duration of 1 to 2 years.
Michel Farnier, Helen M Colhoun, William J Sasiela, Jay M Edelberg, Gaëlle Asset

J Clin Lipidol· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Navigating the Future of Cardiovascular Drug Development-Leveraging Novel Approaches to Drive Innovation and Drug Discovery: Summary of Findings from the Novel Cardiovascular Therapeutics Conference.
Thomas J Povsic, Rob Scott, Kenneth W Mahaffey, Robert Blaustein, Jay M Edelberg

Cardiovasc Drugs Ther· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Alirocumab on Lipoprotein(a) Over ≥1.5 Years (from the Phase 3 ODYSSEY Program).
Daniel Gaudet, Gerald F Watts, Jennifer G Robinson, Pascal Minini, William J Sasiela, Jay Edelberg

Am J Cardiol· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Endothelial microparticles: sophisticated vesicles modulating vascular function.
Anne M Curtis, Jay Edelberg, Rebecca Jonas, Wade T Rogers, Jonni S Moore

Vasc Med· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relationship of microparticles to progenitor cells as a measure of vascular health in a diabetic population.
Anne M Curtis, Lifeng Zhang, Elizabeth Medenilla, Ming Gui, Patrick F Wilkinson, Jay M Edelberg

Cytometry B Clin Cytom· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis